New and Existing Patients
Already a patient?
Login or sign-upto Connect Patient Portal to make an appointment
Locations and Appointments
New Patients
Insurances Accepted
Please contact the doctor's office to verify that your insurance is accepted.
AETNA
Aetna - NYP
Amida Care
Anthem Blue Cross Blue Shield
Anthem Blue Cross/Blue Shield
CIGNA
EmblemHealth
Fidelis Care
GHI
Health Insurance Plan of NY (HIP)
Healthfirst
Healthspring
Local 1199
Molina Healthcare
Oxford Health Plans
Quality Health Management (QHM)
Rockefeller University/Luminare
United Healthcare
UnitedHealthcare
WellCare
WorldWide Medical
About Richard R. Furman, M.D.
Dr. Furman is Director of the CLL Research Center at Weill Cornell Medicine and a member of the Lymphoma/Myeloma Service in the Division of Hematology/Oncology. His area of focus is on the development of non-chemotherapeutic approaches to treating CLL, and has played an integral part in the development of ibrutinib and idelalisib.
For More Videos, please see below:
Board Certifications
- Hematology
- Internal Medicine
- Medical Oncology
Expertise
- Chronic Lymphocytic Leukemia
- CLL (Chronic Lymphocytic Leukemia)
- Hodgkin's Disease
- Idiopathic Thrombocytopenic Purpura
- Leukemia
- Non-Hodgkin's Lymphoma
- Waldenstrom's Macroglobulinemia
Education
- Fellowship: Mount Sinai School of Medicine
- Medical School: Mount Sinai School of Medicine
- Residency: Mount Sinai School of Medicine
Languages
- English
Titles & Positions
- Associate Attending Physician
- Attending Physician
- Morton Coleman, M.D. Distinguished Professor of Medicine
- Professor of Medicine
Hospital Affiliations
- NewYork-Presbyterian / Weill Cornell Medical Center
Education
- Medical School: Mount Sinai School of Medicine
- Fellowship: Mount Sinai School of Medicine
- Residency: Mount Sinai School of Medicine
Titles & Positions
- Associate Attending Physician
- Attending Physician
- Morton Coleman, M.D. Distinguished Professor of Medicine
- Professor of Medicine
Board Certifications
- hematology
- internal medicine
- medical oncology
Languages Spoken
- english
Research
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
July 28, 2026Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
June 09, 2026Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up.
April 08, 2026